June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint
Jan 27, 2025, 08:52

Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint

Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:

“Every time they approve a drug based on non-survival endpoint, they give us some excuse.

I have collected those excuses. There are seven of them. In this new column in Medscape , I and Dr. Sharon Batt, a cancer survivor and regulatory science expert, list these seven arguments and specifically respond to each of them to demonstrate why OS still remains the most patient centric endpoint for cancer drug trials.

Please do read.

This is NOT another “surrogates are bad” paper.

We specifically address the concerns raised against OS.

I hope you’ll be convinced.”